Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01969708 · ClinicalTrials.gov registry record · Phase 3
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
A Phase 3 study, sponsored by The Emmes Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 362
- Enrollment target
NCT01969708 is a Phase 3 study that has completed, run by The Emmes Company. The registered enrollment target is 362 participants.
The verdict
NCT01969708, a Phase 3 study, has completed, sponsored by The Emmes Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 362 participants
- Enrollment target
Study Summary
SCORE2 is a multicenter, prospective, randomized, phase III clinical trial in which all participants enrolled will be followed for up to 2.5 years. SCORE2 is designed as a non-inferiority trial, with study eyes randomized to intravitreal bevacizumab (1.25 mg) every 4 weeks vs. intravitreal aflibercept (2.0 mg) every 4 weeks. SCORE2 aims to determine if bevacizumab is non-inferior to aflibercept for the treatment of macular edema associated with central retinal vein occlusion (CRVO), with the primary outcome of visual acuity measured at Month 6.
Interventions
- DRUG bevacizumab
- DRUG aflibercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 362 participants |
| Start Date | 2014-09 |
| Est. Completion | 2021-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01969708
The ClinicalTrials.gov registry entry for NCT01969708 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 362 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Emmes Company, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which bevacizumab is the first listed.
NCT01969708 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01969708 about?
NCT01969708 is a clinical study titled "Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)". SCORE2 is a multicenter, prospective, randomized, phase III clinical trial in which all participants enrolled will be followed for up to 2.5 years. SCORE2 is designed as a non-inferiority trial, with study eyes randomized to intravitreal bevacizumab (1.25 mg) every 4 weeks vs. intravitreal afliberce...
What is the current status of trial NCT01969708?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 362 participants. The study started on 2014-09. Estimated completion is 2021-03.
What interventions are being tested in trial NCT01969708?
The interventions under investigation include: bevacizumab (DRUG), aflibercept (DRUG).
Who is sponsoring clinical trial NCT01969708?
This trial is sponsored by The Emmes Company, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.